ESTRO 2025 - Abstract Book

S1804

Clinical – Upper GI

ESTRO 2025

Results: A total of 348 lesions in 297 patients were included ( Table1 ), 177 patients from OligoCare and 120 from MOMENTUM; registry inclusion: April 2019–May 2023. The median follow-up was 14.5 months. Most common primary tumor origins: colorectal (61%), breast (13%) and lung (13%). Treatment was given in 1-12 fractions, with median planned BED 98 of 108Gy (IQR, 73–173Gy). For the full cohort, 1- and 2-year LC was 88.3% and 84.1%, respectively; 1- and 2-year OS: 79.6% and 53.5%, respectively. Univariate analyses showed a significant better LC for BED 98 >100Gy and MRI vs. CBCT (1-year LC 94.5% for MRI, 83.5% for CBCT); significant better OS for smaller CTV and BED 98 >100Gy; both LC and OS were significantly worse for N lesions >1 and lung vs. breast cancer.